This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
COMPASS Pathways PLC Sponsored ADR (CMPS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Pediatrix (MD) Down 4.2% Despite Q1 Earnings & Revenue Beat
by Zacks Equity Research
Investors are likely concerned about Pediatrix's (MD) lower enrollment in commercial insurance programs, escalating practice salaries and benefits and net borrowings.
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and COMPASS Pathways PLC Sponsored ADR (CMPS) have performed compared to their sector so far this year.
All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong Buy
by Zacks Equity Research
COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?
by Zacks Equity Research
Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and Geron (GERN) have performed compared to their sector so far this year.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
by Andrew Rocco
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
COMPASS Pathways PLC Sponsored ADR (CMPS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
COMPASS Pathways PLC Sponsored ADR (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 289% Upside in COMPASS Pathways PLC Sponsored ADR (CMPS): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 288.6% upside potential for COMPASS Pathways PLC Sponsored ADR (CMPS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 781% Upside in COMPASS Pathways PLC Sponsored ADR (CMPS): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 781.4% in COMPASS Pathways PLC Sponsored ADR (CMPS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The Zacks Analyst Blog Highlights: PSY, PSIL, Atai Life Sciences, COMPASS Pathways and Field Trip Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PSY, PSIL, Atai Life Sciences, COMPASS Pathways and Field Trip Health.
3 Psychedelic Stocks to Play the Shroom Boom
by Sejuti Banerjea
Psychedelic substances are often grouped together with cannabis, but there are some important distinctions. ATAI, CMPS and FTRP are some of the best stocks in the space.
Is the Options Market Predicting a Spike in COMPASS Pathways (CMPS) Stock?
by Zacks Equity Research
Investors need to pay close attention to COMPASS Pathways (CMPS) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in COMPASS Pathways (CMPS) Stock?
by Zacks Equity Research
Investors need to pay close attention to COMPASS Pathways (CMPS) stock based on the movements in the options market lately.
Zacks Industry Outlook Highlights: Avantor, Eurofins Scientific, GoodRx Holdings, Apollo Medical and COMPASS Pathways
by Zacks Equity Research
Zacks Industry Outlook Highlights: Avantor, Eurofins Scientific, GoodRx Holdings, Apollo Medical and COMPASS Pathways
5 Top Medical Services Stocks to Beat COVID-Led Industry Challenges
by Urmimala Biswas
Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Services industry. AVTR, ERFSF, GDRX, AMEH and CMPS are poised to gain.